ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,071.63
0.02%
US Tech 100
16,917.20
-0.84%
Dow Jones
38,460.92
-0.11%
Brent Oil
87.315
0.11%
Bitcoin
63,893.28
-0.60%
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. PTC Therapeutics Inc (PTCT) Quote

PTC Therapeutics Inc

PTC Therapeutics Inc (PTCT)

NASDAQ
25.21
-0.20
(-0.79%)
Closed April 24 4:00PM
Delayed by 15 minutes
25.21
0.00
( 0.00% )
Pre Market: 4:00AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
25.21
Bid
18.60
Ask
38.19
Volume
-
0.00 Day's Range 0.00
17.53 52 Week Range 59.84
Market Cap
1.931B
Previous Close
25.21
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
862,708
Shares Outstanding
76,608,030
Dividend Yield
-
PE Ratio
-3.08
Earnings Per Share (EPS)
-8.18
Revenue
1.07B
Net Profit
-626.6M

About PTC Therapeutics Inc

PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is... PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.ptcbio.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
PTC Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PTCT. The last closing price for PTC Therapeutics was $25.21. Over the last year, PTC Therapeutics shares have traded in a share price range of $ 17.53 to $ 59.84.

PTC Therapeutics currently has 76,608,030 shares outstanding. The market capitalization of PTC Therapeutics is $1.93 billion. PTC Therapeutics has a price to earnings ratio (PE ratio) of -3.08.

PTCT Latest News

More News

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire WARREN, N.J., April 23, 2024 WARREN, N.J., April 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc...

April 23 2024
PR Newswire (US)

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results PR Newswire SOUTH PLAINFIELD, N.J., April 11, 2024 SOUTH PLAINFIELD, N.J., April 11, 2024 /PRNewswire/...

April 11 2024
PR Newswire (US)

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA PR Newswire SOUTH PLAINFIELD, N.J., March 28, 2024 - First marketing authorization submission for sepiapterin with...

March 28 2024
PR Newswire (US)

PTC Therapeutics Provides Key Regulatory Updates

PTC Therapeutics Provides Key Regulatory Updates PR Newswire SOUTH PLAINFIELD, N.J., March 19, 2024 - BLA submitted to FDA for Upstaza™ for the treatment of AADC deficiency - - NDA to be...

March 19 2024
PR Newswire (US)

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J., Feb. 29, 2024 – 34% year-over-year growth in 2023...

February 29 2024
PR Newswire (US)

PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SOUTH PLAINFIELD, N.J., Feb. 27, 2024 SOUTH PLAINFIELD, N.J., Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc...

February 27 2024
PR Newswire (US)

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH PLAINFIELD, N.J., Feb. 22, 2024 SOUTH PLAINFIELD, N.J., Feb. 22, 2024 /PRNewswire/ -- PTC...

February 22 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

February 16 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.080.31834460803825.1326.4924.01134293225.30665967CS
4-4.27-14.484396200829.4829.8324.0185026826.45557063CS
12-1.03-3.9253048780526.2432.90523.5886270827.64239034CS
262.310.039284155422.9132.90517.53106654225.64341634CS
52-27.55-52.217589082652.7659.8417.53103940030.6122912CS
156-20.95-45.385615251346.1659.8417.5376233736.5799151CS
260-11.94-32.139973082137.1570.8217.5371821040.95700563CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ILAGIntelligent Living Application Group Inc
$ 0.8301
(53.72%)
1.9M
AIREreAlpha Tech Corporation
$ 1.61
(38.79%)
1.03M
CDTXCidara Therapeutics Inc
$ 16.11
(31.08%)
12.17k
MRINMarin Software Incorporated
$ 2.95
(25.00%)
14
NUWENewellis Inc
$ 0.31
(22.97%)
145.66k
ZAPPZapp Electric Vehicles Group Ltd
$ 2.67
(-31.71%)
467
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.3113
(-26.80%)
311.8k
FBLGraniteShares ETF Trust GraniteShares
$ 20.11
(-24.88%)
52.39k
BPTSBiophytis SA
$ 8.00
(-17.55%)
334
JAKKJAKKS Pacific Inc
$ 20.20
(-13.90%)
90
SBFMSunshine Biopharma Inc
$ 1.11
(19.35%)
1.92M
ILAGIntelligent Living Application Group Inc
$ 0.8301
(53.72%)
1.9M
AIREreAlpha Tech Corporation
$ 1.61
(38.79%)
1.03M
SQQQProShares UltraPro Short QQQ
$ 12.12
(2.62%)
921.57k
TQQQProShares UltraPro QQQ
$ 52.26
(-2.70%)
427.65k

PTCT Discussion

View Posts
Monksdream Monksdream 4 weeks ago
PTCT over $20
👍️0
DayTraderOG DayTraderOG 3 years ago
Power hour PTCT let go
👍️0
DayTraderOG DayTraderOG 3 years ago
Great news out $PTCT https://ir.ptcbio.com/news-releases/news-release-details/spinal-muscular-atrophy-sma-foundation-and-ptc-therapeutics
👍️0
DayTraderOG DayTraderOG 3 years ago
Lol at the ask wild ride wee weee
👍️0
DayTraderOG DayTraderOG 3 years ago
Wow what a day
👍️0
DayTraderOG DayTraderOG 3 years ago
Wow already jumping up
👍️0
DayTraderOG DayTraderOG 3 years ago
Hello $PTCT
👍️0
r clarke r clarke 4 years ago
Anything pushing this higher next year?
Debt is already a tad high, when will another
offering be needed?
👍️0
whytestocks whytestocks 5 years ago
News: $PTCT PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J. , Oct. 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that data from STRIDE,* the first international registry for patients with Duchenne muscular dystrophy due to a nonsense mutation receiving Translarnaä (ataluren), de...

In case you are interested PTCT - PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
👍️0
whytestocks whytestocks 5 years ago
News: $PTCT PTC Provides Update on Translarna(TM) (ataluren) Application for Label Expansion

SOUTH PLAINFIELD, N.J. , June 28, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has completed their review of a proposed indication extension of Translar...

Read the whole news https://marketwirenews.com/news-releases/ptc-provides-update-on-translarna-tm-ataluren-application-for-l-8429210.html
👍️0
wiltonio wiltonio 7 years ago
GREAT POINT PARTNERS LLC has filed a new 13G, reporting 5.24% ownership in $PTCT - https://fintel.io/soh/us/ptct/great-point-partners-llc and https://fintel.io/i/great-point-partners-llc
👍️0
XenaLives XenaLives 7 years ago
Closing in on a charting target - anyone want to comment on the pipeline?

👍️0
chainma1l chainma1l 7 years ago
That's pretty significant. It was a no-brainer after they bought Emflaza. The market reaction was irrationally negative. I didn't think PTCT would move this quickly back up, but I'm glad I got back in when I did.
glty
👍️0
wiltonio wiltonio 7 years ago
Complete Pharma Holdings II, LLC has filed a new 13G, reporting 16.2% ownership in $PTCT - https://fintel.io/so/us/ptct
👍️0
wiltonio wiltonio 7 years ago
RTW INVESTMENTS, LLC has filed a new 13G, reporting 5.2% ownership in $PTCT - https://fintel.io/so/us/ptct
👍️0
stocktrademan stocktrademan 7 years ago
PTCT bullish 8.64









normal chart




log chart



👍️0
trendmkr trendmkr 7 years ago
Here’s What Happened To Karyopharm Therapeutics Inc and PTC Therapeutics, Inc. https://marketexclusive.com/heres-what-happened-to/78614/?icd1
👍️0
chainma1l chainma1l 7 years ago
Bummer. I dumped my remaining shares pre-market. Possibility I'll buy back at some point, but I think PTCT has a while before anything positive happens.
Good luck all.
👍️0
chainma1l chainma1l 7 years ago
Credit Suisse Says PTC Therapeutics Could Trade Up Between $80 And $100

https://finance.yahoo.com/news/credit-suisse-says-ptc-therapeutics-154545551.html

👍️0
chainma1l chainma1l 7 years ago
Marathon getting $89k for DMD drug. Administration pushing for lower drug prices, so competition in this space would be good in that respect. PTC will be pushing the FDA on this.
Dip seems good for investors. I don't see this as bad news for PTC. Just the opposite. I realize the patients who potentially benefit from Marathon's drug and Ataluren drug are initially different. Interesting that SRPT was up on the news.

http://www.wsj.com/amp/articles/marathon-pharmaceuticals-to-charge-89-000-for-muscular-dystrophy-drug-1486738267

http://wincountry.com/news/articles/2017/feb/09/fda-approves-marathon-pharmaceuticals-dmd-drug/
👍️0
chainma1l chainma1l 7 years ago
Orphan drug designation:

http://www.prnewswire.com/news-releases/rg7916-granted-orphan-drug-designation-in-the-us-for-the-treatment-of-spinal-muscular-atrophy-300386964.html

I would expect the premarket volume to be higher than it is.
👍️0
chainma1l chainma1l 7 years ago
PTC Therapeutics announces its JV w/ Roche (RHHBY) and the SMA Foundation initiated a clinical study (FIREFISH) in infants with Type I SMA

FIREFISH is a two-part study.
•Part one is an open-label, dose escalation study in at least 8 infants for a minimum of 4 weeks. ?The primary objective of part one is to assess the safety profile of RG7916 in infants and determine the dose for part two.

•Part two is an open-label, single-arm study in !40 infants with Type I SMA for 24 months, followed by an open-label extension. ?The primary objective of part two is to assess the efficacy of RG7916 at the selected dose over a 12-month treatment period.

•A trial in childhood onset (Type II/III) SMA patients, SUNFISH, is currently enrolling the dose escalation portion of the study.
•Commencement of the pivotal portion of either study will trigger a $20 mln milestone payment to co from Roche (RHHBY).

This was announced a while back, but PTC announced the initiation of the study today. This started in 2006, so hopefully things can move along to help the kids who are affected.

http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-initiation-of-firefish-study-in-infant-type-i-sma-patients-300386262.html



👍️0
stocktraderMNT stocktraderMNT 7 years ago
$PTCT Day Trading Idea for November 14 https://goo.gl/BEAOQ0
👍️0
stocktrademan stocktrademan 7 years ago
PTCT bearish 11.30

no position just watching chart


















normal chart


log chart

👍️0
ClayTrader ClayTrader 7 years ago
* * $PTCT Video Chart 11-11-16 * *

Link to Video - click here to watch the technical chart video
👍️0
beambe beambe 7 years ago
good Volume
👍️0
ClarkKant ClarkKant 7 years ago
Yeah 2nd short here it's easier to see the short opportunities than it is the bounces. Everyone can make $$ on both sides of the coin here.
👍️0
cjstocksup cjstocksup 7 years ago
PTCT was a cash cow from pre market from $9.80 to over $11.00 missed that second dip because I was gone but sold all my shares at $11.10. GL
👍️0
ClarkKant ClarkKant 7 years ago
Nice bounce Time to short again $11.20 no brainer
👍️0
ClarkKant ClarkKant 7 years ago
Awesome short from $11+!
👍️0
PStockPickz PStockPickz 7 years ago
wow PM is nuts right now
👍️0
Moto260 Moto260 7 years ago
Or Short
👍️0
Moto260 Moto260 7 years ago
Well made quite the run today. Was a good one. Broke trend line now. Possible play later in the week. =D
👍️0
r clarke r clarke 7 years ago
Man did this take a hit today!
👍️0
chainma1l chainma1l 7 years ago
Approvals somewhere. Earnings were decent and they are moving forward, although the language in the portion about EMA wasn't exactly confidence inspiring, at least they are not blowing smoke. Guidance was conservative as well.
👍️0
r clarke r clarke 7 years ago
Up over 2% on a down day. Anyone bullish here?

... what catalyst would be needed to take this higher?
👍️0
trendmkr trendmkr 8 years ago
Ups And Downs In Biotech This Week: PTC Therapeutics, Puma Biotechnology and Nektar Therapeutics http://marketexclusive.com/ups-downs-biotech-week/34468/?icd1
👍️0
girlfriend girlfriend 8 years ago
Thank you and nice trade!
👍️0
ClarkKant ClarkKant 8 years ago
They'll do a 2nd level appeal to FDA like SRPT but not much hope. Plus they got bad news in Europe as well.

You can't short PTCT because it's on the 'no short' stock list so hopes of any type of short squeeze is out and it looks like all the institution holders are still unloading.

Just sold my $9 PUTS here @ $6.95 for 5x bagger but could be going back to $5s soon.
👍️0
girlfriend girlfriend 8 years ago
So is there any hope for PTCT going forward? Would love to swing trade this again hopefully from the 5's
👍️0
ClarkKant ClarkKant 8 years ago
There is your $7.75 to $8.40 10-minute bounce get out while you can at these levels
👍️0
ClarkKant ClarkKant 8 years ago
Going back to $5s by the end of the month crippling news
👍️0
ClayTrader ClayTrader 8 years ago
* * $PTCT Video Chart 10-17-16 * *

Link to Video - click here to watch the technical chart video
👍️0
ClarkKant ClarkKant 8 years ago
Sad bounce $9.05 to $9.35 going down more.
👍️0
Options2Wealth Options2Wealth 8 years ago
Great call on SMMT!

My only regret is that after first reading your post, I only bought a very small position for tracking purpose only...Today when I opened my account and saw SMMT double, my first reaction was that Ameritrade must be having a system glitch. Wish I had done some due diligence after taking a tracking position...

Since you have clearly done your research on SMMT, where do you see this going...

I apologize for the Off-Topic post.

On PTCT, I expect the stock to resume its upward move. When it prints $17.01, it will be ready to close the yawning $10 gap above. So I am looking for a $14 move, a double from here(!), by the end of the year. First stop: $17.01

contax
👍️0
ClayTrader ClayTrader 8 years ago
* * $PTCT Video Chart 09-30-16 * *

Link to Video - click here to watch the technical chart video
👍️0
CHIKILIN CHIKILIN 8 years ago
$14.17 @ 1:05 PM
👍️0
chainma1l chainma1l 8 years ago
Something new happen?
👍️0
chainma1l chainma1l 8 years ago
SC13G today: Camber Capital Management LLC reports 5.84 pct passive stake in PTC Therapeutics Inc as of Sept. 19.

http://www.reuters.com/article/idUSFWN1C50HP?type=companyNews
👍️0
legalizeMJ legalizeMJ 8 years ago
SMMT has more upside potential because its pps is the smallest, only $9.6 per share AND on 9/26/16, SMMT Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy(DMD).
👍️0

Your Recent History

NASDAQ
PTCT
PTC Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved